Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs M 281 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Momenta Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2018 to 1 Jan 2019.
    • 10 Dec 2018 Status changed from planning to recruiting.
    • 04 Oct 2018 According to a Momenta Pharmaceuticals media release, the company will host a live webcast of its R and D day on 11 Oct 2018, which will include a presentation of indications for the planned phase 2 proof of concept studies (this and other 295848).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top